AR098614A1 - Compuesto para el tratamiento de hipoglicemia severa - Google Patents

Compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
AR098614A1
AR098614A1 ARP140104512A ARP140104512A AR098614A1 AR 098614 A1 AR098614 A1 AR 098614A1 AR P140104512 A ARP140104512 A AR P140104512A AR P140104512 A ARP140104512 A AR P140104512A AR 098614 A1 AR098614 A1 AR 098614A1
Authority
AR
Argentina
Prior art keywords
treatment
compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
ARP140104512A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR098614A1 publication Critical patent/AR098614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente se refiere a un compuesto útil en el tratamiento de hipoglicemia. Composición farmacéutica.
ARP140104512A 2013-12-18 2014-12-04 Compuesto para el tratamiento de hipoglicemia severa AR098614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917597P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
AR098614A1 true AR098614A1 (es) 2016-06-01

Family

ID=52278802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104512A AR098614A1 (es) 2013-12-18 2014-12-04 Compuesto para el tratamiento de hipoglicemia severa

Country Status (27)

Country Link
US (1) US9695225B2 (es)
EP (1) EP3083668A1 (es)
JP (1) JP2017509584A (es)
KR (1) KR20160075825A (es)
CN (1) CN105814076A (es)
AP (1) AP2016009242A0 (es)
AR (1) AR098614A1 (es)
AU (1) AU2014366424B2 (es)
BR (1) BR112016012067A2 (es)
CA (1) CA2928985A1 (es)
CL (1) CL2016001472A1 (es)
CR (1) CR20160226A (es)
DO (1) DOP2016000096A (es)
EA (1) EA201690914A1 (es)
EC (1) ECSP16024798A (es)
GT (1) GT201600117A (es)
HK (1) HK1224304A1 (es)
IL (1) IL245400A0 (es)
MA (1) MA39109B1 (es)
MX (1) MX2016007982A (es)
NZ (1) NZ719463A (es)
PE (1) PE20160848A1 (es)
PH (1) PH12016501182A1 (es)
SG (1) SG11201604154SA (es)
TN (1) TN2016000181A1 (es)
TW (1) TW201609127A (es)
WO (1) WO2015094875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2020163125A1 (en) 2019-02-05 2020-08-13 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2008205229B2 (en) * 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
MX2010012695A (es) * 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
PT2718318T (pt) * 2011-06-10 2018-11-09 Hanmi Science Co Ltd Derivados de oxintomodulina inovadores e composição farmacêutica para tratar a obesidade compreendendo os mesmos
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9944687B2 (en) * 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
CA2877358A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity

Also Published As

Publication number Publication date
MX2016007982A (es) 2016-09-09
US9695225B2 (en) 2017-07-04
ECSP16024798A (es) 2017-05-31
CL2016001472A1 (es) 2017-03-10
IL245400A0 (en) 2016-06-30
BR112016012067A2 (pt) 2017-09-26
JP2017509584A (ja) 2017-04-06
PE20160848A1 (es) 2016-09-10
AP2016009242A0 (en) 2016-06-30
MA39109B1 (fr) 2018-04-30
AU2014366424A1 (en) 2016-05-19
GT201600117A (es) 2017-07-06
CA2928985A1 (en) 2015-06-25
KR20160075825A (ko) 2016-06-29
CN105814076A (zh) 2016-07-27
AU2014366424B2 (en) 2017-02-16
DOP2016000096A (es) 2016-08-15
HK1224304A1 (zh) 2017-08-18
EA201690914A1 (ru) 2016-09-30
NZ719463A (en) 2017-09-29
SG11201604154SA (en) 2016-07-28
TW201609127A (zh) 2016-03-16
MA39109A1 (fr) 2017-09-29
US20160311881A1 (en) 2016-10-27
PH12016501182A1 (en) 2016-07-25
CR20160226A (es) 2016-07-12
WO2015094875A1 (en) 2015-06-25
EP3083668A1 (en) 2016-10-26
TN2016000181A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
ES2964927T3 (es) Composiciones para el tratamiento de plantas
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
UY36075A (es) Derivados de tubulisina
GT201500247A (es) Imidazopiridazinas sustituidas
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DOP2016000142A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
GT201600117A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
CL2016000171A1 (es) Formulación de metaxalona.
ZA201509091B (en) Antivirally effective pharmaceutical composition
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
ES1078913Y (es) Dispositivo de avance mandibular combinado con depresion lingual para el tratamiento del ronquido.
TH127247B (th) องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง

Legal Events

Date Code Title Description
FB Suspension of granting procedure